NEC Bio B.V.

Routebeschrijving Website Contact opnemen met het bedrijf

NEC Bio B.V. NEC Bio's mission is to develop groundbreaking therapies for patients around the globe through the use of advanced AI technologies.

If you are at ESMOIO, feel free to reach out to Dr. Heinz Lubenau, and learn more about our new phase I data for orally ...
24/12/2025

If you are at ESMOIO, feel free to reach out to Dr. Heinz Lubenau, and learn more about our new phase I data for orally available, lymph node-targeted DNA vaccination, NECVAX-NEO1. We presented our poster yesterday in the therapeutic development category at the conference.

In this photo, from L to R we have Dr. Domas Vaitiekus, Dr. Álvaro Aranguren Ibáñez, Dr. Vincas Urbonas MBBS, MSc, PhD, and Dr. Heinz Lubenau. We thank our collaborators who help us to clinically advance this asset.

For more information reach out to us at [email protected] or visit our website: www.nec-bio.com

Last week Dr. Heinz Lubenau, CEO NEC Bio Therapeutics GmbH, was invited to the 2nd Personalized Cancer Vaccine Summit in...
24/12/2025

Last week Dr. Heinz Lubenau, CEO NEC Bio Therapeutics GmbH, was invited to the 2nd Personalized Cancer Vaccine Summit in Boston. He presented the results from our AI-powered salmonella based oral personalized cancer vaccine program, NECVAX-NEO1, currently in the clinic.

We thank the event organizers for the opportunity and look forward to continue engaging with the oncology community.

Reach out to us on [email protected], or here, to engage with us in knowing how we are transforming the drug development space with our cutting-edge and explore partnership opportunities in the field of and .

Akira Kitamura, Saverio Niccolini, Kaïdre Bendjama, Akhilesh Sharma

https://www.nec.com/en/press/202512/global_20251210_02.html
24/12/2025

https://www.nec.com/en/press/202512/global_20251210_02.html

NEC Bio Therapeutics today presents results from the Phase I basket clinical trial of an orally administered cancer vaccine, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) for treating patients with solid tumors.

https://www.nec.com/en/press/202511/global_20251128_03.html
24/12/2025

https://www.nec.com/en/press/202511/global_20251128_03.html

The Japanese Foundation for Cancer Research (JFCR), NEC Corporation (NEC), and Taiho Pharmaceutical Co., Ltd. (Taiho) have signed a three-party joint research (Joint Research) agreement aimed at developing new cancer vaccines through the utilization of whole-genome information.

https://www.nec.com/en/press/202511/global_20251105_02.html?cid=snsli20251107
24/12/2025

https://www.nec.com/en/press/202511/global_20251105_02.html?cid=snsli20251107

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, will jointly present additional immunological data profiling the immune response af...

02/09/2025

先日、東京で に関するメディア勉強会を開催しました。医療・製薬業界を担当する30名以上の記者の方々にご参加いただき、NECの研究開発の取組みについて直接ご紹介する貴重な機会となりました。
当日は、 #がん研究会有明病院 先端医療開発科部長の北野滋久先生をお招きし、進歩の著しい #がん免疫療法 について、また #個別化医療 の開発の一環としてNECも取り組む #ネオアンチゲンワクチン についてご講演いただきました。
さらに、NEC AI創薬統括部長の北村哲、トランスレーショナルリサーチプロフェッショナルの小野口和英が登壇し、NECが #創薬 に を活用する背景や狙い、そしてAI創薬実用化に向けた歩みを紹介しました。
NECの北米研究所や欧州研究所、NEC Bioで培ったAI技術を創薬に応用することで、新しい医薬品開発の可能性を広げています。

Recently, we hosted a media seminar on AI drug development in Tokyo. More than 30 journalists covering the healthcare and pharmaceutical industries joined us, making it a valuable opportunity to share NEC’s research and development efforts.
We were honored to welcome Dr. Shigehisa Kitano, Director, Department of Advanced Medical Development at Cancer Institute Hospital of Japanese Foundation for Cancer Research, who gave an insightful talk on the remarkable progress in cancer immunotherapy as well as on personalized medicine initiatives such as neoantigen vaccines, an area where NEC is also actively engaged.
In addition, Akira Kitamura, Head of NEC AI Drug development, and Dr. Kazuhide Onoguchi from Translational Research shared NEC’s vision for applying AI to drug development and our journey toward practical implementation.
By leveraging AI technologies originally developed at our NEC Laboratories America and NEC Laboratories Europe and NEC Bio, NEC is driving innovation in drug development.

Adres

Evert Van De Beekstraat 354
Schiphol
1118CZ

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer NEC Bio B.V. nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Contact Opnemen Met Het Bedrijf

Stuur een bericht naar NEC Bio B.V.:

Snelkoppelingen

Delen

Bedrijven in de buurt